KRRO earnings analysis
What we found in KRRO's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
For Q1 2026, Korro Bio, Inc. reported a significant decline in collaboration revenue, falling to $0 from $2.6 million in Q1 2025, aligning with a strategic pause on collaboration with Novo Nordisk. Despite a reduction in operating expenses, the company recorded a net loss of $19.6 million, an improvement from the prior year's $23.4 million. The firm maintains a substantial cash position of $157.1 million, bolstered by a recent successful PIPE, allowing anticipated operations to extend into the second half of 2028.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Net Loss Improved
- Net loss for Q1 2026 was $19.6 million, improved from $23.4 million in Q1 2025.
- Cash and Security Position Strong
- As of March 31, 2026, the company reported cash, cash equivalents, and marketable securities totaling $157.1 million.
- Decrease in Operating Expenses
- Total operating expenses decreased to $20.436 million from $27.570 million in Q1 2025.
- Successful Capital Raising
- Closed a PIPE in March 2026, raising approximately $85.0 million.
- Collaboration Revenue Halted
- Collaboration revenue dropped to $0 from $2.6 million due to a pause in the Novo Nordisk agreement.
- Improved Loss from Operations
- Loss from operations narrowed to $20.4 million, down from $25.0 million in Q1 2025.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Extend of Net Operating Loss
- Accumulated deficit reached $403.5 million as of March 31, 2026, raising liquidity concerns.
- Ongoing Dependence on External Financing
- The company anticipates the need for further capital as it does not expect revenue from product sales for several years.
- Impact of Regulatory Changes
- Future regulatory changes, especially regarding clinical and manufacturing processes, could complicate operations.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-19.625
What they said about what is next.
Outlook deferred to earnings press release / call.
The filing reads about the same as the one before it.
What came before.
- 10-K · March 12, 2026
- Korro Bio, Inc.'s 2025 10-K report highlights significant operational changes as the company navigates through its clinical development phase while facing significant losses. The launch of its KRRO-121 therapy targeting…
- 10-Q · November 12, 2025
- Korro Bio, Inc. reported a mixed Q3 2025, with actual revenue of $1.09 million surpassing estimates by 28.7%, although operating losses reduced only slightly compared to the prior period. The company is grappling with…
- 10-Q · August 12, 2025
- Korro Bio, Inc. reported disappointing financial results for Q2 2025, with a revenue of $1.46 million compared to the consensus estimate of $406.9 million. Operating losses increased, with a reported EPS of -2.74. The…
- 10-Q · May 7, 2025
- Korro Bio, Inc. reported a net revenue of $2.6 million in Q1 2025, up from $0 in Q1 2024, marking a significant improvement due mostly to its collaboration with Novo Nordisk. However, the company continues to incur…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing KRRO makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever